A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Recruiting at 3 trial locations

Overseen By EunJeong Seo

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: ImmuneOncia Therapeutics Inc.

Must not be taking: CD47 agents

Disqualifiers: CNS disease, Active infection, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

12 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing IMC-002, a new drug, in adults with advanced or recurring cancers. Researchers aim to understand how the drug works in the body and its effects on cancer.

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications, but you cannot take certain drugs within 28 days before starting the study treatment.

Research Team

HEUNG TAE KIM

Principal Investigator

ImmuneOncia Therapeutics Inc.

Eligibility Criteria

Inclusion Criteria

Signed informed consent form (ICF)

Histologically or cytologically proven metastatic or locally advanced solid tumors and relapsed or refractory lymphomas, for which no standard therapy known to prolong survival exists or have relapsed/refractory/PD following the last line of treatment

Solid tumors must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Lymphomas must have at least 1 measurable lesion according to the Lugano criteria with the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive escalating doses of IMC-002 to assess safety and tolerability

Expansion Cohorts

Participants receive IMC-002 at the recommended Phase 2 dose to further evaluate safety

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• IMC-002

Participant Groups

Group I: IMC-002 Experimental Treatment 1 Intervention

Dose escalation will follow the traditional 3+3 design.

Who Is Running the Clinical Trial?

ImmuneOncia Therapeutics Inc.

Lead Sponsor

Trials

5

Recruited

130+